P2RY12 and atrial fibrillation: Finally, a Canadian, prospective, observational study comparing ticagrelor with clopidogrel in 277 patients with AF and MI treated with PCI on triple therapy found no differences in MACE or bleeding risk, irrespectively of the type of P2Y12 inhibitor.40 Considering the totality of evidence, the clear preference of clopidogrel over the more potent P2Y12 inhibitors may be questionable.